Anzeige
Mehr »
Login
Freitag, 26.04.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Wie die Revolution der sauberen Energie eine solide Investitionsmöglichkeit bieten könnte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
164 Leser
Artikel bewerten:
(0)

A-Share Listed Biological Products Companies (2016-2020) - Biotechnological Advances & Favorable Policies Will Facilitate Fast Growth - Research and Markets


DUBLIN, May 12, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "A-Share Listed Biological Products Companies - Profiles and Financial Data" report to their offering.

Research and Markets Logo

In China, biological products include: bacterial vaccines (containing toxoid), viral vaccines, antitoxin and antiserum, blood products, cytokine, growth factors, enzyme, in vivo and in vitro diagnostic products, and other biological active preparations.

According to this report, fast economic growth and residents' increasing income have pushed up people's medical expenses. China's biological products market outperforms the global average. In China, the market size exceeded CNY 130 billion in 2016, but its share in the pharmaceutical market was less than 10%, far below that in developed countries.

In the Thirteenth Five-Year Plan (2016-2020), biotechnological pharmaceuticals, new vaccines, new cell therapy preparations and other innovative pharmaceuticals were listed among the priorities of the bio-medicine industry. It is expected that in the next few years, biotechnological advances and favorable policies will facilitate fast growth of the biological product industry.

The report is composed of two parts: the first part is enterprise profiles and the second part is the operation status of these enterprises in the recent decade.

Companies Mentioned

  • Ginwa Enterprise (Group) Inc.
  • Beijing Tiantan Biological Products
  • Shanghai Fosun Pharmaceutical
  • Bluestar Adisseo Company
  • Shanghai Jiaoda Onlly
  • Zhongyuan Union Cell & Gene Engineering
  • Zhejiang Qianjiang Biochemical
  • Tonghua Dongbao Pharmaceutical
  • Autobio Diagnostics
  • Wuhan Thalys Medical Technology
  • Shenzhen Cau Technology
  • Shenzhen Neptunus Bioengineering
  • Zhenxing Biopharmaceutical & Chemical Inc.
  • Jiangsu Sihuan Bioengineering
  • Changchun High-Tech Industry
  • Hualan Biological Engineering
  • Shanghai Kehua Bio-engineering
  • DAAN Gene
  • Beijing SL Pharmaceutical
  • Shanghai RAAS Blood Products
  • Shandong Sinobioway Biomedicine
  • Changsheng Bio-technology
  • Anhui Anke Biotechnology (Group)
  • Chongqing Chifei Biological Products
  • Walvax Biotechnology
  • Staidson (Beijing) Biopharmaceuticals
  • Baotou Dongbao Bio-Tech
  • (10+ Others)

Key Topics Covered:

1. Financial Indexes

2. Summary of Income Statement

3. Summary of Balance Sheet

4. Summary of Cash Flow Statement

For more information about this report visit http://www.researchandmarkets.com/research/n924xc/ashare_listed

Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2017 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.